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Results am shown in the table. CVRref was 32 • 0,7 before mtenmntton 
and 3,1 ± 0,8 after 6 months, 
Conofusmn: Guidance of CVRd by CVRmf instead of fixed era-Oft !ovals 
~liOWS to K~ntify pla with ~ low lnodenCa of mstenosis after coronary slant 
mtl~mtat~n, 
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~ Mul!k~lN)r Alpldn and Ti¢!opldlne Trial After 
Intrl¢ofm~ry 81miring In High Risk Patients 
P Urban, C, IMaca~a, H- J  Rgppm¢f~t, F- Klen~neij, H, I~manuet~son, 
A. Fontanelli, M~ Pleper, 1'. Wes.~eling, L, Sagnard. FOr the MAT]IS 
e,a~gro~,d: The ~at~n ol ~ne  (T) and a~pinn (A) has been 
ShOwn tO be supenm tO amtvltamin, K agents (AVK) and aspnn following 
O~rO*la w ~ ~ft~a.,r~l~ Rt lOW nsk ~l~nts, b~ AVK * A remains an 
unl~ro~n mfe~ ~ fo, ~ nsk paints. 
~ .  350 ~ nsk pal~,~ tram 31 ho~o~ale were Centrally ~ano~rn. 
L~ed within 6 hours after ~ imp~n~tmn to receive either/~.50 m~ .t. T 
500 m~ m A 250 rag/day • AVK (INR 2.5-3) for 1 month (open label)~ 
The pm~ary ~ e~d..t~mt was dehned as ~ occurrence of death, 
AMI, CABG o~ repeat mte~m~on at 30 days. The ~ r y  e~pe~ot was 
the mOdesce of rnalo~ vascu~ and 10~eeding compl~at~.  Pat;enl~ were 
e|~t~e afire stem m~ptamal~n if one of ~ra l  st the folk~wng were present 
1 ) stent(s) m ~  to Ireal ab~ clOSUre after FTCA: 2) ang,~gfaphy a~er 
stentmg sUao~mal; 3) >_3 stems use~ o~ ~e~,~h of~e s~med sege~,~ _~45 
ram; 4) nominal d~m~er ,.~ ~mgest ba~x~n inflated m the slant -:2.5 mm 
Resut~- The pm, rtary endpom~ was r ~  for I0 palmms (5.6%) m the 
A + T and 19(11%) rathe A + AVK group. (RR 1.9, C109-4.1, p =0.07}. The 
secondary e ~  was more frequent in the A + AVK group (12 patmnts, 
69%), than m the A + T group (3 pa~er~, 1.7% (RR 4.1, CI 1.2-14.3, p 
0.O2). 
Condus~0ns- hKjh n~ p~ents fo~ovm~g cc, rona~y s~em .~ta~on 
~ ba heated w~"~ A + T rather than A • AVK since ~e bleeding and 
vascular comp~,,~ons are s~, - . i f~  reduced and there ~ a marked trend 
suggesting a dec,mesa in cardiac events at 30 (/ays. 
Predictors of Outcome in Cardiogenic Shock 
Wednesday, April 1, 1998, 4:00 p.m.-5:00 p.m. 
Georgia Wodd Congress Center, Room 267W 
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t~ '~-~ Outcomes With Pulmonary Artery Cathete~t ion  in 
Cardiogenic Shock 
V. Menon. L& Sleeper. R. Fincke, J.S. Hoohman ~r the SHOCK 
I~tom:  ~. Luke's-Rooseve/f Hospttal Center, Cotun'~a Un~ars~, 
New Yod~. NY, USA 
Puknoaary Artery catheterzzatmn (PAC) has been assooaled wrth increased 
mortahty but its use in Card~ogemC Shock (CS) is wK/espread. The SHOCK 
Registry is a prospeot~e database o1 patients ~ suspeoted CS following 
A~I. T'~ eva~ua~e the intpact ot PAC, baseline variables, bamodynamics and 
outcomes m 567 patients who received PAC were compared to 263 palmnts 
managed without PAC. A "propens=ty score" for PAC p~acement was denved 
from a logistic regression model using baseline vanables and adjusted mor- 
tality rates were compared. Patients receiving PAC were signific ntfy younger 
(67.5 ± 11.4 vs7 ~ .b ± 11.6 yrs, p < 0,0001), were more likely 1o be transfers 
(46% vs 27%. p < 0.0001), had less pnor MI (35 vs 48%, p = 0.008) and 
developed CS later (7.8 vs 4.5 median hrs, p = 0.005). Although lowest SBP 
(69 + 18 vs 69 ± 19 ram, p = 0.816) and MI location were similar, pabents 
with PAC had increased HR (99 ¢ 25 v,s 89 _ 28, p = 0.0001 ), SBP (92 ± 21 
vs77 ± 20ram, p= < 0,0001) and DBP (55 ± t5va45 ± 20ram. p = 0,0001) 
with morn inotmpe use and were more likely to undergo cath. PTCA, IABP 
and CABG (p < 0.0001) with decreased in hospital mortality (56 vs 79%, p 
< 0.0001) but no impact on LOS. Even after adjusting for baseline variables 
(PAC propensity) patients receiving PAC had lowered mortality (OR 0.458 
95% CI 0.31-0.67. Chi-square 15.4, p = 0.0001). 
Conclusion: PAC use in suspected CS is associated with aggressive 
therapy and a lower in hospital mortality. Selection bias is evident but no 
harm associated with PAC was demonstrated. 
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Mecnanicsl  I.sft Ventrx:umr Support  Using 
Quam!t l t lve  Echcc41rdlography 
AA M~h~fa, RL, Karats, WA Mandanno, S. Murali, I !P  Gnft~h, 
J, ~an,  IlL Unlve~ity ot PtttSburgh, ~ PA, USA 
Profound myoe, afd~! (~s~ may b~ fe~miblQ, A~srnent Of fml¢- 
tioea! m~'ove~t after ~ st an LV assmt ~ (WAD) for cae~oge~c 
shock r~11~n~ ¢!ink:~!ly ¢haller,~ng. To d~effl1~,~_  got~mt~l fo4r wea~ 
from LVAD support u!ing quantilatfve cho, 12 pts, a~ 48 ~ 18 ym were 
studied O~seasea w~,~ pest.¢ardtofomy shock in 0 (~xonary ~ 5, 
heart ~ lant  2, valve ~ 1), ~ ~ral myocare~s in ~, po~t mfa~ 
shock in 1, and ~ lum callz~a~p~pa1~,v m 1, LVADs ~ :  I ~ u s  
5, Abiome~ 4 Th~,,atec 2, and N¢ ~a¢or ! Dur~bo~ o! suppo,t was 15 ± 21 
days, ~ur -~.s  Of mid.LV shod ~*S ~ i ¢  area (EDA), 
area (ESA), ,.nd @a!  area cl~nge [FAC = (EDA - ESA),~EDA] were 
made (luring .~n LVAD flow: 4.6 ± 0.4 L/ram and uurmg weamng to low 
LVAD flow: 1.9 _+ 0.9 L/rain, 3even pts had success~! removal st LVAD 
(incfud~g Thoratec removal in 1) and survived to hOSl~al discharge. Five 
pts remained LVAD dependent: 4 died wllhin 7 days, 1 w~S t~amq31anted. 
Baseline LV FAC >20% o~ im~ement  in LV FAC % ~, >20% from h~ 
1o low LVAD flow was predictive o! successful LVAD removal (p ¢ 0.05). All 
LVAD dependenl pts could not increase FAC > 15% w~ low LVAD flow 
le 
@ Lv~.~a,~,  , *  
~m~ LVAD Dl~a~Wllf ~n l l l  
10 
~wm ~ ~ Low 
Con¢'/u~on: Quant~1~ve cho may I~e useful to assess myocardial re- 
covery ~n p~ On LVAD support and aid in the climcal decl=on for LVAD 
removal. 
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[ -9 - -~ Gender and Other Predictors o f  intraaorttc Balloon 
Pump Complications: Prospecl ive Study of 1,119 
Consecut ive Patients at Single High Volume, Tefllary 
Cam Center 
MS. Dawson, C Kop~lansky. R McBride, M. Cohen. Allegheny UnfversRy 
ot the Health Science=s, PttilaOe~a. PA. USA 
Bat*ground" Th~s prospecl~e study exarmned the complications assooatea 
w~th intraao~c balloon (lAB) counterpufsatton and the role of gender ,n the 
current era. 
Mefttods: We evaluated 1,119 cor~ecuhve percutaneous lAB mserttons 
at Aflegheny Unwersdy Hos~s ,  Hahnemann Div~on from January 1993 
to June 1997 Aft patients were followed prospectively ~ a daily clinical 
evaluation. Mator complications were darrned as balloon rupture, embotism 
or Irmb tschem~a requmng surgery, bleeding requinng transfuston, system.: 
fnfec~on, or death clue to one of the above. 
ResuffS There were 727 men end 392 women (age, 65 ± 11 ym.); 
,nctdence of diabetes (27%), hypertensmn (52%), or penpharal vascular 
disease (8%) A total of 166 compficatmns occurred and a malor complication 
occurred m 126 of 1,119 patients (11%). Multivanate Iogist¢ rogmsszon 
analysis ot ~ge, cerd~ac index, body surface area (BSA), gender, ciiab4E~Bs, 
and penpheral vasculw disease (PVD) as covanates, io~ltified PVD (relative 
nsk, RR = 4.1), female gender (RR = 23). and BSA (RR = 0.26 pet m ~) 
as independent predictors of a malor complication. Defining "high risk', as 
women or patients with BSA < 1.8 m 2 . cardiac index -.22, diabetes or PVD, 
predicted 150 complicabons ~mong 818 patients (18%) compared to 16 
complications among 301 "low risk" patients (5%) (p < 0.0001). 
Corcluslon: Despite reductions in sizes of lAB and sheath, the current 
complication rate associated with intreaortic eunterpulsation remains high. 
Advances in lAB technology need to focus on the "high risk" subset of patients 
that ineluu~ worn,=,1, or smaller patients, and these with PVD. 
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